FéCO-OPSA: Improvement of Executive Functions With the CO-OP Method in the Adult Subject After Stroke

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Terminated
CT.gov ID
NCT04282564
Collaborator
(none)
3
1
3
25.1
0.1

Study Details

Study Description

Brief Summary

The research focuses on top-down intervention approaches and more specifically on the Cognitive Orientation to daily Occupational Performance (CO-OP) method in the rehabilitation of executive function disorders in adult post-stroke subjects in chronic phase. The main objective of this study is therefore to improve performance in significant activities of daily living for people with chronic post-stroke dysexecutive disorders.

Condition or Disease Intervention/Treatment Phase
  • Other: Co-OP treatment
N/A

Detailed Description

Today, approaches to intervention with adults after stroke can be categorized into two groups: bottom-up approaches (neurodevelopmental, sensory integration, mental imagery, cognitive stimulation, perceptual-motor/kinesthetic training...) and top-down approaches (task-oriented approach, neuromotor task training, occupational performance coaching, the CO-OP approach). Although bottom-up intervention approaches have existed for several years longer than top-down approaches, in general, top-down intervention approaches have shown better results.

In the latest work with post-stroke adults with objective cognitive impairment, the data indicate the relevance of CO-OP in improving performance and satisfaction, attention, inhibition and flexibility or apathy.

This study aims to demonstrate the effectiveness of the CO-OP approach in adult post-stroke patients in chronic phase, specifically on planning function, through the Single Case Experimental Design methodology by randomized intervention (3 patients) over 6 weeks of treatment and 10 weeks of evaluation.

Study Design

Study Type:
Interventional
Actual Enrollment :
3 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Improvement of Executive Functions With the CO-OP Method in the Adult Subject After Stroke
Actual Study Start Date :
Feb 24, 2020
Actual Primary Completion Date :
Mar 29, 2022
Actual Study Completion Date :
Mar 29, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: CO-OP Arm (early phase A)

Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 3 weeks.

Other: Co-OP treatment
The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as "a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery". The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke

Experimental: CO-OP Arm (mid phase A)

Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 2.5 weeks.

Other: Co-OP treatment
The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as "a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery". The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke

Experimental: CO-OP Arm (late phase A)

Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 2 weeks.

Other: Co-OP treatment
The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as "a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery". The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke

Outcome Measures

Primary Outcome Measures

  1. Improved performance in significant activities of daily living [10 weeks]

    Improved performance in significant activities of daily living will be measured bi-weekly by the Canadian Occupational Performance Measurement. The score is between 1 to 10

  2. Improved performance in significant activities of daily living [10 weeks]

    Improved performance in significant activities of daily living will be measured bi-weekly by the Performance Quality Rating Scale. The score is between 1 to 10

Secondary Outcome Measures

  1. improvement in the sense of personal effectiveness [10 weeks]

    The improvement in the sense of personal effectiveness will be measured by New General Self-Efficacy Scale (8 questions with response to 1 for strongly disagree to 5 for strongly agree)

  2. Analytically measure of executive functions [10 weeks]

    The analytical improvement of executive functions will be measured by the Trail Making Tes

  3. Analytically measure of executive functions [10 weeks]

    The analytical improvement of executive functions will be measured by the number span (WAIS IV)

  4. Analytically measure of executive functions [10 weeks]

    The analytical improvement of executive functions will be measured by the Stroop test

  5. Analytically measure of executive functions [10 weeks]

    The analytical improvement of executive functions will be measured by the test "the Tower of London"

  6. Analytically measure of executive functions [10 weeks]

    The analytical improvement of executive functions will be measured by the Wisconsin Card Sorting test

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Stroke responsible for a dysexecutive syndrome authenticated by the GREFEX battery

  • Stroke more than 6 months old (chronic phase)

  • Social security affiliation

  • Signing of a free and informed consent following clear and detailed information.

Exclusion Criteria:
  • Disorder of comprehension objectified by the - LAnguage Screening Test (LAST) (minimum score 4/8 in expression and 6/7 in comprehension)

  • Significant anosognosia of dysexecutive syndrome

  • Pregnant women

  • Neurological condition other than stroke or psychiatric disorder

  • Patient following a rehabilitation with a liberal therapist targeting executive functions during the period of participation in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital of Toulouse Toulouse France 31000

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Xavier De Boissezon, MD, University Hospital, Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT04282564
Other Study ID Numbers:
  • RC31/19/0448
First Posted:
Feb 24, 2020
Last Update Posted:
Jun 6, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Toulouse
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 6, 2022